Pharming’s Leniolisib On Track To Become First Disease-Modifying APDS Drug
Following NDA Acceptance
The Dutch firm’s US filing for its first-in-class PI3K inhibitor has been accepted under priority review, bringing the asset closer to becoming the first disease-modifying option for a rare, genetic disorder.
